Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$35.25
+0.2%
$40.21
$31.01
$50.21
$17.96B0.644.45 million shs3.58 million shs
Insulet Co. stock logo
PODD
Insulet
$187.27
+1.0%
$171.20
$125.82
$313.02
$13.12B11.06 million shs723,372 shs
ResMed Inc. stock logo
RMD
ResMed
$218.57
-0.6%
$197.71
$132.24
$229.97
$32.11B0.641.20 million shs450,553 shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$355.64
+0.4%
$378.36
$310.42
$415.73
$25.91B1.05574,817 shs434,699 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
0.00%-1.23%-11.09%-14.48%-17.60%
Insulet Co. stock logo
PODD
Insulet
0.00%+12.88%+13.68%-1.96%-40.20%
ResMed Inc. stock logo
RMD
ResMed
0.00%+2.22%+23.06%+21.12%-2.41%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.00%-2.35%-5.75%-1.77%+2.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.8656 of 5 stars
3.13.03.34.02.51.72.5
Insulet Co. stock logo
PODD
Insulet
4.9385 of 5 stars
4.43.00.04.92.30.83.1
ResMed Inc. stock logo
RMD
ResMed
4.6485 of 5 stars
2.41.03.34.53.91.72.5
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.8631 of 5 stars
2.43.03.33.23.32.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.20
Hold$45.7329.72% Upside
Insulet Co. stock logo
PODD
Insulet
2.82
Moderate Buy$239.4427.86% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-7.22% Downside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
2.80
Moderate Buy$435.2022.37% Upside

Current Analyst Ratings

Latest WST, RMD, BAX, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2024
Insulet Co. stock logo
PODD
Insulet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$213.00 ➝ $200.00
5/10/2024
Baxter International Inc. stock logo
BAX
Baxter International
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$40.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$226.00 ➝ $234.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$218.00 ➝ $213.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$255.00 ➝ $260.00
5/7/2024
Insulet Co. stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/3/2024
Baxter International Inc. stock logo
BAX
Baxter International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$41.00 ➝ $44.00
(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$14.81B1.21$5.25 per share6.72$16.16 per share2.18
Insulet Co. stock logo
PODD
Insulet
$1.70B7.73$3.79 per share49.35$11.29 per share16.59
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.60$7.81 per share27.99$31.52 per share6.93
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.95B8.78$10.18 per share34.94$36.80 per share9.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
$2.66B$5.206.7811.051.8417.79%18.47%4.91%7/25/2024 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$3.3056.7549.813.3713.14%34.06%9.08%8/13/2024 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5133.5725.362.6920.91%24.43%15.70%8/1/2024 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$593.40M$7.5846.9238.836.2619.42%20.57%15.47%7/25/2024 (Estimated)

Latest WST, RMD, BAX, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Insulet Co. stock logo
PODD
Insulet
$0.39$0.73+$0.34$0.73$424.05 million$441.70 million    
5/2/2024Q1 2024
Baxter International Inc. stock logo
BAX
Baxter International
$0.61$0.65+$0.04$1.23$3.55 billion$3.59 billion    
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
4/25/2024Q1 2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.29$1.56+$0.27$1.57$670.62 million$695.40 million    
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$1.163.29%+6.70%22.31%8 Years
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.88%+5.66%29.49%12 Years
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.800.22%+5.81%10.55%31 Years

Latest WST, RMD, BAX, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Quarterly$0.200.22%7/31/20247/31/20248/7/2024
5/7/2024
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.293.2%5/31/20245/31/20247/1/2024
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
2/20/2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Quarterly$0.200.23%4/23/20244/24/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.35
1.48
1.01
Insulet Co. stock logo
PODD
Insulet
1.72
3.74
2.75
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.03
2.61
1.95

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
Insulet Co. stock logo
PODD
Insulet
0.47%
ResMed Inc. stock logo
RMD
ResMed
1.21%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000509.58 million508.51 millionOptionable
Insulet Co. stock logo
PODD
Insulet
3,00070.04 million69.71 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,60072.84 million72.46 millionOptionable

WST, RMD, BAX, and PODD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Baxter International logo

Baxter International

NYSE:BAX
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
West Pharmaceutical Services logo

West Pharmaceutical Services

NYSE:WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.